Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
02 Avril 2024 - 10:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice
President, Head of Research and Development. Dr. Thompson will lead
research and development at Acadia and serve as a member of the
company’s Executive Leadership Team, reporting to Steve Davis,
Chief Executive Officer of Acadia.
“Liz is a preeminent drug research and development leader with
extensive experience in the advancement and commercialization of
first in class therapies,” said Steve Davis, Chief Executive
Officer. “Her passion and expertise for developing new medicines
that address areas of high unmet need will be a huge asset to
Acadia and an important addition to our executive leadership team.
Her leadership will be instrumental as we continue to advance our
early and late stage assets in rare disease and central nervous
system disorders and pursue opportunities to further expand our
pipeline of medicines.”
“I am thrilled to join Acadia at such a pivotal time,” said Liz
Thompson, Executive Vice President, Head of Research and
Development. “With two commercial products on the market and a
strong pipeline of potential opportunities in rare disease and
central nervous system disorders, we are poised for long term
growth as we continue delivering new therapies to benefit patients
and their families.”
Dr. Thompson most recently served as Executive Vice President,
Research and Development (Rare Disease) at Amgen following its
acquisition of Horizon Therapeutics plc. At Horizon, Dr. Thompson
led the R&D organization and oversaw the rapid realization of
the company's goal to become a science-based biopharma. She joined
Horizon in 2018 and served in roles of increasing responsibility
that culminated at Executive Vice President, Research and
Development. Prior to joining Horizon, she held roles at AbbVie,
Raptor, InterMune, and Amgen in a career spanning clinical
development, business development and medical communications and
has been involved in pre- or post-market R&D activities for
life-changing drugs including TEPEZZA®, KRYSTEXXA®, UPLIZNA®,
RAVICTI®, SKYRIZI®, ESBRIET®, and ENBREL®. She has served the
broader biotech ecosystem as a member of California Life Sciences,
an industry advocacy organization, and as a member of the board of
directors of IGM Biosciences. She has also been recognized for her
dedication to the healthcare industry and mentorship and
sponsorship of others as a 2021 Healthcare Businesswomen’s
Association Luminary. Dr. Thompson received a B.S. in chemistry
from Harvey Mudd College and a Ph.D. in macromolecular and cellular
structure and chemistry from The Scripps Research Institute.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on Prader-Willi syndrome,
Alzheimer’s disease psychosis and multiple other programs targeting
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at Acadia.com and follow us on LinkedIn
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402387189/en/
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024